Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 4/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1395813 | 0.88 | MCL1 (0.44) | PARP1HTR1AMCL1HTR3ATSHR | |
| SCHEMBL30955312 | 0.88 | MCL1 (0.44) | PARP1HTR1AMCL1HTR3ATSHR | |
| SCHEMBL12021863 | 0.87 | ADRA2A (0.50) | PARP1HTR1AMEN1LMNAKMT2A | |
| SCHEMBL2266482 | 0.86 | PARP1 (0.41) | PARP1HTR1AMCL1HTR3ATSHR | |
| SCHEMBL12037714 | 0.85 | PARP1 (0.41) | PARP1HTR1AMCL1HTR3ATSHR | |
| SCHEMBL6798145 | 0.85 | PARP1 (0.41) | PARP1HTR1AMCL1HTR3ATSHR | |
| SCHEMBL2335955 | 0.82 | PARP1 (0.49) | PARP1HTR1ALMNACYP2D6HTR3A | |
| SCHEMBL19305557 | 0.76 | PARP1 (0.50) | PARP1MEN1KMT2ATDP1CYP2D6 | |
| SCHEMBL29407494 | 0.76 | PARP1 (0.50) | PARP1MEN1KMT2ATDP1CYP2D6 | |
| SCHEMBL12021871 | 0.76 | PARP1 (0.40) | PARP1HTR1AHTR3AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030018056-A1 | Substituted guanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2003-01-23 | — | — | US | claimed |
| EP-1238971-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-09-11 | — | — | EP | claimed |
| EP-3129065-B1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | AKAMARA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-3672582-B1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS SINAI MEDICAL CENTER (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12569486-B2 | Calmodulin inhibitors, CHK2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4229055-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | NOVARTIS AG (CH) | 2026-03-04 | — | — | EP | disclosed |
| US-12560609-B2 | Biomarkers predictive of cancer cell response to ML329 or a derivative thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260015316-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250388597-A1 | BIFUNCTIONAL PHOTOCROSSLINKING PROBES FOR COVALENT CAPTURE OF PROTEIN-NUCLEIC ACID COMPLEXES IN CELLS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-12-25 | — | — | US | disclosed |
| US-12503526-B2 | Nickel catalysts with single alkali ions for homopolymerization and copolymerization | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250361333-A1 | METHODS FOR PREPARING COPOLYMERS AND FOR THE OXIDATIVE DEGRADATION THEREOF | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-11-27 | — | — | US | disclosed |
| US-6734205-B2 | SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2004-05-11 | — | — | US | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| US-20030096856-A1 | Cell proliferation inhibitors | ABBVIE INC. | 2003-05-22 | — | — | US | disclosed |
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
| US-6521658-B1 | Cell proliferation inhibitors | ABBOTT LABORATORIES | 2003-02-18 | — | — | US | disclosed |
| US-20030018056-A1 | Substituted guanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1238971-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-09-11 | — | — | EP | disclosed |
| EP-0975624-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | Takeda Chemical Industries, Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046590-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569486-B2 | Calmodulin inhibitors, CHK2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies | RPS6KA1, RPS6KA2, RPS6KA3 | PARP1 468/4885HTR1A 2850/4885MEN1 3923/4885 |
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | MKI67, CDKN1A, CDK4 | PARP1 579/4885HTR1A 3572/4885MEN1 976/4885 |
| US-12560609-B2 | Biomarkers predictive of cancer cell response to ML329 or a derivative thereof | KEAP1, NFE2L2, NQO1 | PARP1 526/4885HTR1A 4532/4885MEN1 2749/4885 |
| US-20030096856-A1 | Cell proliferation inhibitors | MKI67, CCNI, CCNA1 | PARP1 705/4885HTR1A 3458/4885MEN1 757/4885 |
| US-20250388597-A1 | BIFUNCTIONAL PHOTOCROSSLINKING PROBES FOR COVALENT CAPTURE OF PROTEIN-NUCLEIC ACID COMPLEXES IN CELLS | PCNA, DDB1, DCLRE1A | PARP1 25/4885HTR1A 3662/4885MEN1 1975/4885 |
| US-20030018056-A1 | Substituted guanidine derivatives | SLC28A1, SLC7A1, ABCB11 | PARP1 1943/4885HTR1A 894/4885MEN1 2803/4885 |
| US-20260015316-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | GLI1, RCC2, BRCA1 | PARP1 3540/4885HTR1A 2868/4885MEN1 181/4885 |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | PARP1 516/4885HTR1A 3530/4885MEN1 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.